Wall Street equity research analysts covering ALX Oncology Holdings (NASDAQ: ALXO) maintain an average consensus 12-month price target ranging between $4.50 and $4.60 per share. These projections reflect institutional evaluations of its ongoing clinical-stage trials, cash runway metrics, and the therapeutic potential of its CD47 blocking pipeline assets in competitive oncology markets.